Replies to post #76473 on NanoViricides Inc. (NNVC)

[Puffer]

The easiest way to price the market is to look at current sales of TamiFlu and Relenza. A drug that actually works is expected to exceed those in sales, hence management's estimate of $4-$7B in annual sales. Just take a conservative whack at something around $2B in global sales and you get into the same $9-$10B ballpark as PCYC. $10B equates to a share price around $200.....that's enough of a nosebleed that you don't need to get wild with your projections. Of course that would be the projection on FluCide alone, giving zero value to the other pipeline candidates.... and zero value as well to the the ability to create anti-virals on demand.